The stromal-tumor amplifying STC1-Notch1 feedforward signal promotes the stemness of hepatocellular carcinoma

Abstract

Background Cancer-associated fibroblasts (CAFs), an important component of the tumor microenvironment (TME), play crucial roles in tumor stemness. It has been shown in various cancer studies that stanniocalcin-1 (STC1) is secreted by CAFs, however, its function in HCC is still not clear. Methods The serum concentration and intracellular expression level of STC1 were quantified by ELISA and western blotting, respectively. The role of CAF-derived STC1 in HCC stemness was investigated by sphere formation, sorafenib resistance, colony formation, and transwell migration and invasion assays in vitro and in an orthotopic liver xenograft model in vivo. An HCC tissue microarray containing 72 samples was used to evaluate the expression of STC1 and Notch1 in HCC tissues. Coimmunoprecipitation (CoIP) and dual-luciferase reporter assays were performed to further explore the underlying mechanisms. ELISAs were used to measure the serum concentration of STC1 in HCC patients. Results We demonstrated that CAFs were the main source of STC1 in HCC and that CAF-derived STC1 promoted HCC stemness through activation of the Notch signaling pathway. In HCC patients, the expression of STC1 was positively correlated with Notch1 expression and poor prognosis. The co-IP assay showed that STC1 directly bound to Notch1 receptors to activate the Notch signaling pathway, thereby promoting the stemness of HCC cells. Our data further demonstrated that STC1 was a direct transcriptional target of CSL in HCC cells. Furthermore, ELISA revealed that the serum STC1 concentration was higher in patients with advanced liver cancer than in patients with early liver cancer. Conclusions CAF-derived STC1 promoted HCC stemness via the Notch1 signaling pathway. STC1 might serve as a potential biomarker for the prognostic assessment of HCC, and the stromal-tumor amplifying STC1-Notch1 feedforward signal could constitute an effective therapeutic target for HCC patients.

Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer

“…STC1 is a glycoprotein associated with calcium and phosphorus metabolism [44] that has been detected in various human tissues [45] . In addition, dysregulated STC1 expression has been identified in various cancers [46] . In OC, STC1 serves an oncogenic role and promotes metastasis and chemoresistance [47] .…”

Maresin1 alleviates liver ischemia/reperfusion injury by reducing liver macrophage pyroptosis

“…Western blotting was conducted as previously reported [ 12 ]. Briefly, cell proteins were lysed in RIPA buffer with phosphatase inhibitors and protease inhibitor (Sigma, USA).…”

Novel insights into Notch signaling in tumor immunity: potential targets for cancer immunotherapy

“…Notch1 activation in TNBC cells promoted contact-dependent induction of CXCL8 in inflammation-induced TNBC-stromal interaction network, leading to TNBC metastasis and progression ( 80 ). CAF-derived stanniocalcin 1 (STC1) increased the stemness of HCC cells ( 81 ). Mechanistically, STC1 directly combined with Notch1 receptors to motivate the Notch signaling pathway.…”